Please use this identifier to cite or link to this item:
http://dx.doi.org/10.25673/92704
Title: | Gut microbiota profiles and the role of anti-CdtB and anti-vinculin antibodies in patients with functional gastrointestinal disorders (FGID) |
Author(s): | Vasapolli, Riccardo Schulz, Christian Schweden, Melanie Casèn, Christina Kirubakaran, Graceline Tina Kirste, Katrine Hånes Macke, Lukas Link, Alexander Schütte, Kerstin Malfertheiner, Peter |
Issue Date: | 2021 |
Type: | Article |
Language: | English |
URN: | urn:nbn:de:gbv:ma9:1-1981185920-946602 |
Subjects: | Cytolethal distending toxin/ vinculin Dysbiosis Faecal microbiota Functional dyspepsia Irritable bowel syndrome |
Abstract: | Background: Distinct faecal microbiota profiles are reported to be associated with various subtypes of IBS. Circulating antibodies to cytolethal distending toxin B (CdtB) and vinculin are proposed as biomarkers to identify post-infectious IBS. The aim of our study was to analyse serum levels of anti-CdtB and anti-vinculin antibodies in patients with different functional gastrointestinal disorders (FGID) and their correlation with the composition of faecal microbiome. Methods: The study cohort comprised 65 prospectively recruited individuals: 15 with diarrhoea-type- IBS (IBS-D), 13 with constipation-type- IBS (IBS-C), 15 with functional dyspepsia (FD) and 22 healthy controls. FGID subgroups were defined according to Rome III criteria. Serum levels of anti-CdtB and anti-vinculin antibodies were measured by ELISA. Faecal microbiome composition analysis and assessment of dysbiosis were performed by GA-map ® Dysbiosis Test. Results: Positivity rate either for anti-CdtB or anti-vinculin antibodies was higher in the IBS-C group (76.9%) compared to IBS-D (40.0%), FD (60%) and healthy (63.6%) groups. Dysbiosis was more frequent in subjects positive for anti-CdtB antibodies and in IBS-C patients, who showed an increased amount of opportunistic/pro-inflammatory bacteria and reduced gut protective bacteria. IBS-C patients showed a high inter-individual variation of bacterial communities compared to other FGID subgroups and healthy individuals, whereas microbial profiles of patients with IBS-D and FD were overlapping with those of healthy controls. No bacteria markers showed significant differences between FGID subgroups and healthy controls. Conclusion: Neither anti-CdtB/ anti-vinculin antibodies nor faecal microbial profiles allowed to discriminate between specific FGID subgroups. Dysbiosis was more frequent in patients presenting with anti-CdtB antibodies and in IBS-C patients. |
URI: | https://opendata.uni-halle.de//handle/1981185920/94660 http://dx.doi.org/10.25673/92704 |
Open Access: | Open access publication |
License: | (CC BY-NC-ND 4.0) Creative Commons Attribution NonCommercial NoDerivatives 4.0 |
Sponsor/Funder: | Projekt DEAL 2021 |
Journal Title: | European journal of clinical investigation |
Publisher: | Wiley-Blackwell |
Publisher Place: | Oxford [u.a.] |
Volume: | 51 |
Issue: | 12 |
Original Publication: | 10.1111/eci.13666 |
Page Start: | 1 |
Page End: | 10 |
Appears in Collections: | Medizinische Fakultät (OA) |
Files in This Item:
File | Description | Size | Format | |
---|---|---|---|---|
Vasapolli et al._Gut microbiota_2021.pdf | Zweitveröffentlichung | 410.38 kB | Adobe PDF | View/Open |